Skip to main content
Caplight Logo









MediPrint Ophthalmics

MediPrint Ophthalmics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://mediprintlens.com/

Last Round

Series A

Mar 15, 2022

Total Funding Raised

$6.5M

Company Overview

MediPrint Ophthalmics is a clinical-stage pharmaceutical company developing a proprietary ocular drug delivery portfolio using drug-eluting contact lenses to treat conditions like glaucoma, dry eye, and allergies.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, 3D Printing, Clinical Trials

Business Model

B2B2C

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

drug-eluting contact lensmedicated contact lenssustained drug deliveryglaucoma treatment3D printed contact lensocular drug deliveryeye drop alternativedrug-device combinationcombo productocular hypertensionbimatoprostclinical-stage pharmaceuticaldry eye treatmentpreservative-free lens505(b)(2) pathway

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MediPrint Ophthalmics Comparables

Compare MediPrint Ophthalmics with similar companies based on industry and business-model similarity.

MediPrint Ophthalmics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Freya Ophthalmics
89%
OcuMedic, Inc.
84%
Mati Therapeutics
81%

MediPrint Ophthalmics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 15, 2022
SeedJan 26, 2021

Key People

Founding team and executive leadership

Praful Doshi

CTO, Founder, Chairman, Cto, Founder Chairman

Founding Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2026

    Monthly visitors increased 1050% MoM, from 34 to 391.

  • Oct 29, 2024

    Monthly visitors grew 337% MoM.

MediPrint Ophthalmics Filings

Explore SEC and related filing metadata, where available.

MediPrint Ophthalmics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MediPrint Ophthalmics's valuation, stock price, and market status.

Is MediPrint Ophthalmics a public or private company?

MediPrint Ophthalmics is a private company.

What is the current stock price of MediPrint Ophthalmics?

MediPrint Ophthalmics is a private company with no public stock price. No recent secondary market data is available.

How much is MediPrint Ophthalmics worth (valuation)?

Valuation information for MediPrint Ophthalmics is not publicly available.

Can I buy MediPrint Ophthalmics stock?

MediPrint Ophthalmics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MediPrint Ophthalmics's last funding round?

MediPrint Ophthalmics's most recent funding round was Series A on March 15, 2022.

Who are the main investors in MediPrint Ophthalmics?

Investor information for MediPrint Ophthalmics is not publicly disclosed.

Will MediPrint Ophthalmics IPO soon?

No public IPO plans have been announced for MediPrint Ophthalmics.

How can I track MediPrint Ophthalmics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MediPrint Ophthalmics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range12
Year FoundedN/A
Last FundingMar 15, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?